Overview
Tikva Allocell is developing engineered EBV-specific T-cell therapy for solid tumors, positioning the company in oncology cell therapy rather than AI. Its work targets patients with solid tumors where EBV-directed immune cells may offer a therapeutic approach, based on the financing announcement. The company closed an $8 million Series A round announced July 22, 2026, with proceeds earmarked to advance its engineered T-cell program. The funding context indicates an early-stage biotech focused on moving a lead cell-therapy platform forward.
Funding History
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors
Frequently Asked Questions
- How much has Tikva Allocell raised in total?
- Tikva Allocell has raised a total of $8M across 1 funding round.
- What does Tikva Allocell do?
- Tikva Allocell is developing engineered EBV-specific T-cell therapy for solid tumors, positioning the company in oncology cell therapy rather than AI. Its work targets patients with solid tumors where EBV-directed immune cells may offer a therapeutic approach, based on the financing announcement. The company closed an $8 million Series A round announced July 22, 2026, with proceeds earmarked to advance its engineered T-cell program. The funding context indicates an early-stage biotech focused on moving a lead cell-therapy platform forward.
- Where is Tikva Allocell headquartered?
- Tikva Allocell is headquartered in San Francisco, CA.
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
395 AI funding deals worth $337B tracked in 2026. Complete guide to raising pre-seed, seed, Series A/B/C+ for AI startups. Valuations, metrics VCs demand, top investors (Sequoia, a16z, Lightspeed), and how AI funding differs from traditional tech. Includes real deal sizes, timelines, and founder strategies.